Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMH2FN1)

• Drug Name: Suronacrine maleate Drug Info
• Synonyms: HP-128; Suronacrine maleate < Rec INNM; Rac-9-(Benzylamino)-1,2,3,4-tetrahydroacridin-1-ol maleate

Indication

Disease Entry	ICD 11	Status	REF
Cognitive impairment	6D71	Phase 3	[1]

• Cross-matching ID:
  PubChem CID: 9953907
  CAS Number: CAS 113108-86-4
  TTD Drug ID: DMH2FN1
  VARIDT Drug ID: DR01145

Molecule-Related Drug Atlas

Drug(s) Targeting Norepinephrine transporter (NET)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Acetaminophen	DMUIE76	Allergic rhinitis	CA08.0	Approved	[3]
Amitriptyline	DMK7F9S	Depression	6A70-6A7Z	Approved	[4]
Imipramine	DM2NUH3	Depression	6A70-6A7Z	Approved	[5]
Desipramine	DMT2FDC	Attention deficit hyperactivity disorder	6A05.Z	Approved	[3]
Cocaine	DMSOX7I	Anaesthesia	9A78.6	Approved	[6]
Bupropion	DM5PCS7	Depression	6A70-6A7Z	Approved	[7]
Tapentadol hydrochloride	DMXLSH3	Acute pain	MG31	Approved	[8]
Venlafaxine	DMR6QH0	Anxiety disorder	6B00-6B0Z	Approved	[7]
Trimipramine	DM1SC8M	Major depressive disorder	6A70.3	Approved	[9]
Duloxetine	DM9BI7M	Depression	6A70-6A7Z	Approved	[10]

Drug(s) Targeting Acetylcholinesterase (AChE)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tacrine	DM51FY6	Alzheimer disease	8A20	Approved	[11]
Donepezil	DMIYG7Z	Advanced cancer	2A00-2F9Z	Approved	[12]
Malathion	DMXZ84M	Pediculus capitis infestation	1G00.0	Approved	[13]
Galantamine	DMEO794	Alzheimer disease	8A20	Approved	[14]
Huperzine A	DMMAWLU	Alzheimer disease	8A20	Approved	[15]
Neostigmine	DM6T2J3	Myasthenia gravis	8C6Y	Approved	[16]
YM443	DMNZCI1	Functional dyspepsia	DD90.3	Approved	[17]
Ambenonium	DMOP0BL	Myasthenia gravis	8C6Y	Approved	[18]
Demecarium bromide	DMAYEU1	Open-angle glaucoma	9C61	Approved	[19]
Isoflurophate	DMBSK7X	Glaucoma/ocular hypertension	9C61	Approved	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Acetylcholinesterase (AChE)	TT1RS9F	ACES_HUMAN	Modulator	[2]
Norepinephrine transporter (NET)	TTAWNKZ	SC6A2_HUMAN	Modulator	[2]

References

• [1] Handbook of Dementing Illnesses, Morris John. Page(570).
• [2] Potential clinical use of an adrenergic/cholinergic agent (HP 128) in the treatment of Alzheimer's disease. Ann N Y Acad Sci. 1991;640:263-7.
• [3] Augmentation effect of combination therapy of aripiprazole and antidepressants on forced swimming test in mice. Psychopharmacology (Berl). 2009 Sep;206(1):97-107.
• [4] Treatment of comorbid pain with serotonin norepinephrine reuptake inhibitors. CNS Spectr. 2008 Jul;13(7 Suppl 11):22-6.
• [5] Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry. 2009 Mar 17;33(2):220-8.
• [6] Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. Pharmacol Biochem Behav. 2009 Jul;93(1):75-81.
• [7] Clinically relevant drug interactions with new generation antidepressants and antipsychotics. Ther Umsch. 2009 Jun;66(6):485-92.
• [8] 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
• [9] Antidepressants suppress production of the Th1 cytokine interferon-gamma, independent of monoamine transporter blockade. Eur Neuropsychopharmacol. 2006 Oct;16(7):481-90.
• [10] Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007 Jan;12(1-2):34-42.
• [11] Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action. Int J Clin Pract Suppl. 2002 Jun;(127):6-19.
• [12] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2465).
• [13] Acetylcholinesterase activity in Corbicula fluminea Mull., as a biomarker of organophosphate pesticide pollution in Pinacanauan River, Philippines. Environ Monit Assess. 2010 Jun;165(1-4):331-40.
• [14] [From symptomatic to disease modifying therapy Recent developments in the pharmacotherapy of Alzheimer's disease]. Fortschr Neurol Psychiatr. 2009 Jun;77(6):326-33.
• [15] Huperzine A attenuates cognitive deficits and brain injury in neonatal rats after hypoxia-ischemia. Brain Res. 2002 Sep 13;949(1-2):162-70.
• [16] Screening of acetylcholinesterase inhibitors by CE after enzymatic reaction at capillary inlet. J Sep Sci. 2009 May;32(10):1748-56.
• [17] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [18] Alpha6-containing nicotinic acetylcholine receptors dominate the nicotine control of dopamine neurotransmission in nucleus accumbens. Neuropsychopharmacology. 2008 Aug;33(9):2158-66.
• [19] The effects of topical ocular application of 0.25% demecarium bromide on serum acetylcholinesterase levels in normal dogs. Vet Ophthalmol. 2003 Mar;6(1):23-5.
• [20] Rational design of alkylene-linked bis-pyridiniumaldoximes as improved acetylcholinesterase reactivators. Chem Biol. 2003 Jun;10(6):491-502.